Last reviewed · How we verify
PAXG
PAXG is a drug that targets the PD-1 receptor.
PAXG is a drug that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | PAXG |
|---|---|
| Sponsor | Associazione Italiana per lo Studio del Pancreas |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PAXG works by binding to the PD-1 receptor, which is a protein on the surface of immune cells. This binding blocks the interaction between PD-1 and its ligands, leading to the activation of immune cells and the enhancement of anti-tumor responses.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Hyperthyroidism
Key clinical trials
- Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC (PHASE1, PHASE2)
- Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients (PHASE2)
- Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL) (PHASE3)
- PAXG Out in the Country (PHASE4)
- A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PAXG CI brief — competitive landscape report
- PAXG updates RSS · CI watch RSS
- Associazione Italiana per lo Studio del Pancreas portfolio CI